Syros Pharmaceuticals $SYRS announced on Thursday that its Phase 2 Clinical Trial on lead candidate SY-1425 commenced as the first patient received the dose. The lead candidate is a first-in-class selective retinoic acid receptor alpha (RAR?) agonist, in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). SY-1425 is already marketed in Japan as Amnolake to cure different form of AML. It has commercialization rights for all cancer treatments in North America and Europe